Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19 : A Multicenter, Case-Control, Retrospective, Observational Study
© 2020 by the American Diabetes Association..
OBJECTIVE: Poor outcomes have been reported in patients with type 2 diabetes and coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic approaches for this population.
RESEARCH DESIGN AND METHODS: In a multicenter, case-control, retrospective, observational study, sitagliptin, an oral and highly selective dipeptidyl peptidase 4 inhibitor, was added to standard of care (e.g., insulin administration) at the time of hospitalization in patients with type 2 diabetes who were hospitalized with COVID-19. Every center also recruited at a 1:1 ratio untreated control subjects matched for age and sex. All patients had pneumonia and exhibited oxygen saturation <95% when breathing ambient air or when receiving oxygen support. The primary end points were discharge from the hospital/death and improvement of clinical outcomes, defined as an increase in at least two points on a seven-category modified ordinal scale. Data were collected retrospectively from patients receiving sitagliptin from 1 March through 30 April 2020.
RESULTS: Of the 338 consecutive patients with type 2 diabetes and COVID-19 admitted in Northern Italy hospitals included in this study, 169 were on sitagliptin, while 169 were on standard of care. Treatment with sitagliptin at the time of hospitalization was associated with reduced mortality (18% vs. 37% of deceased patients; hazard ratio 0.44 [95% CI 0.29-0.66]; P = 0.0001), with an improvement in clinical outcomes (60% vs. 38% of improved patients; P = 0.0001) and with a greater number of hospital discharges (120 vs. 89 of discharged patients; P = 0.0008) compared with patients receiving standard of care, respectively.
CONCLUSIONS: In this multicenter, case-control, retrospective, observational study of patients with type 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment. The effects of sitagliptin in patients with type 2 diabetes and COVID-19 should be confirmed in an ongoing randomized, placebo-controlled trial.
| Errataetall: |
CommentIn: Diabetes Care. 2020 Dec;43(12):2906-2909. - PMID 33033068 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Diabetes care - 43(2020), 12 vom: 29. Dez., Seite 2999-3006 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Solerte, Sebastiano Bruno [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Comment |
|---|
| Anmerkungen: |
Date Completed 26.11.2020 Date Revised 25.06.2021 published: Print-Electronic figshare: 10.2337/figshare.12907490 CommentIn: Diabetes Care. 2020 Dec;43(12):2906-2909. - PMID 33033068 Citation Status MEDLINE |
|---|
| doi: |
10.2337/dc20-1521 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315647612 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315647612 | ||
| 003 | DE-627 | ||
| 005 | 20231225155355.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2337/dc20-1521 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1052.xml |
| 035 | |a (DE-627)NLM315647612 | ||
| 035 | |a (NLM)32994187 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Solerte, Sebastiano Bruno |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19 |b A Multicenter, Case-Control, Retrospective, Observational Study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.11.2020 | ||
| 500 | |a Date Revised 25.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a figshare: 10.2337/figshare.12907490 | ||
| 500 | |a CommentIn: Diabetes Care. 2020 Dec;43(12):2906-2909. - PMID 33033068 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 by the American Diabetes Association. | ||
| 520 | |a OBJECTIVE: Poor outcomes have been reported in patients with type 2 diabetes and coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic approaches for this population | ||
| 520 | |a RESEARCH DESIGN AND METHODS: In a multicenter, case-control, retrospective, observational study, sitagliptin, an oral and highly selective dipeptidyl peptidase 4 inhibitor, was added to standard of care (e.g., insulin administration) at the time of hospitalization in patients with type 2 diabetes who were hospitalized with COVID-19. Every center also recruited at a 1:1 ratio untreated control subjects matched for age and sex. All patients had pneumonia and exhibited oxygen saturation <95% when breathing ambient air or when receiving oxygen support. The primary end points were discharge from the hospital/death and improvement of clinical outcomes, defined as an increase in at least two points on a seven-category modified ordinal scale. Data were collected retrospectively from patients receiving sitagliptin from 1 March through 30 April 2020 | ||
| 520 | |a RESULTS: Of the 338 consecutive patients with type 2 diabetes and COVID-19 admitted in Northern Italy hospitals included in this study, 169 were on sitagliptin, while 169 were on standard of care. Treatment with sitagliptin at the time of hospitalization was associated with reduced mortality (18% vs. 37% of deceased patients; hazard ratio 0.44 [95% CI 0.29-0.66]; P = 0.0001), with an improvement in clinical outcomes (60% vs. 38% of improved patients; P = 0.0001) and with a greater number of hospital discharges (120 vs. 89 of discharged patients; P = 0.0008) compared with patients receiving standard of care, respectively | ||
| 520 | |a CONCLUSIONS: In this multicenter, case-control, retrospective, observational study of patients with type 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment. The effects of sitagliptin in patients with type 2 diabetes and COVID-19 should be confirmed in an ongoing randomized, placebo-controlled trial | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Sitagliptin Phosphate |2 NLM | |
| 650 | 7 | |a TS63EW8X6F |2 NLM | |
| 700 | 1 | |a D'Addio, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Trevisan, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Lovati, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Pastore, Ida |e verfasserin |4 aut | |
| 700 | 1 | |a Dell'Acqua, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Ippolito, Elio |e verfasserin |4 aut | |
| 700 | 1 | |a Scaranna, Cristiana |e verfasserin |4 aut | |
| 700 | 1 | |a Bellante, Rosalia |e verfasserin |4 aut | |
| 700 | 1 | |a Galliani, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Dodesini, Alessandro Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Lepore, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Geni, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Fiorina, Roberta Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Catena, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Corsico, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Colombo, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Mirani, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a De Riva, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Oleandri, Salvatore Endrio |e verfasserin |4 aut | |
| 700 | 1 | |a Abdi, Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Bonventre, Joseph V |e verfasserin |4 aut | |
| 700 | 1 | |a Rusconi, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Folli, Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Di Sabatino, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Zuccotti, Gianvincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Galli, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Fiorina, Paolo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes care |d 1979 |g 43(2020), 12 vom: 29. Dez., Seite 2999-3006 |w (DE-627)NLM00042983X |x 1935-5548 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2020 |g number:12 |g day:29 |g month:12 |g pages:2999-3006 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2337/dc20-1521 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2020 |e 12 |b 29 |c 12 |h 2999-3006 | ||